Early test: new asthma drug copy enters human trials
NCT ID NCT07327697
Summary
This early-stage study aims to compare a new biologic medication called QL2302 with an existing drug called Tezspire (tezepelumab). Researchers will give a single dose to 178 healthy volunteers to measure how the body processes each drug, check for safety issues, and see if they trigger immune responses. The study is blinded, meaning neither participants nor researchers know which drug is being given.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.